QP25-25 MHCP Pharmacy Benefit Exclusion for Datroway®, Frindovyx™, Kebilidi™ and Niktimvo™

QP24-25 Commercial Pharmacy Benefit Exclusion for Octreotide Kit, Sandostatin® Kit LAR, and Signifor® LAR injection

QP23-25 Commercial Pharmacy Benefit Exclusion for Kebilidi™, Niktimvo™, Steqeyma® and Yesintek™

QP22-25 Provider Press: Q1 2025

QP21-25 Appropriate Use of Modifier -25

MHCP Pharmacy Program Policy Activity Effective May 1, 2025

MHCP Pharmacy Program Policy Activity Effective April 1, 2025

2025 Group Plan Enrollment/Waiver Form - Spanish

2025 Group Plan Enrollment/Waiver Form

2025 Medicare Step-by-Step Guide - Spanish

Guía Paso a Paso de Medicare. Comprenda sus beneficios, opciones y próximos pasos.